Inhaled versus nebulised tobramycin: A real world comparison in adult cystic fibrosis (CF)

M. J. Harrison; M. McCarthy; C. Fleming; C. Hickey; C. Shortt; J. A. Eustace; D. M. Murphy; B. J. Plant

doi:10.1016/j.jcf.2014.04.004

Inhaled versus nebulised tobramycin: A real world comparison in adult cystic fibrosis (CF)

M. J. Harrison
, M. McCarthy
, C. Fleming
, C. Hickey
, C. Shortt
, J. A. Eustace
, D. M. Murphy
, B. J. Plant

School of Medicine

University College Cork

Research output: Contribution to journal › Article › peer-review

Abstract

Background: There are no published data on real-life clinical experience comparing inhaled antibiotic therapy via new rapid delivery systems with nebulised antibiotic therapy in CF. This real world study compares safety, effectiveness and tolerability using tobramycin inhaled powder (TIP) versus tobramycin inhaled solution (TIS). Methods: Adult patients with CF commencing TIP (n=78) completed a questionnaire assessing safety, efficacy, tolerability, patient-satisfaction and self-reported adherence to TIS at baseline and during 12months of TIP therapy. FEV₁% predicted and exacerbation rate were recorded at each visit. Results: There was a significant improvement in adherence scores, with a significant decrease in the number of intravenous antibiotic courses received during 12. months of TIP compared with the preceding 12. months using TIS. 94% of patients who had previously used TIS preferred TIP therapy over TIS. Conclusions: Inhaled powder tobramycin in CF is associated with improved adherence, tolerability and decreased exacerbation rates compared to nebulised treatment in real-life practice.

Original language	English
Pages (from-to)	692-698
Number of pages	7
Journal	Journal of Cystic Fibrosis
Volume	13
Issue number	6
DOIs	https://doi.org/10.1016/j.jcf.2014.04.004
Publication status	Published - 1 Dec 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.jcf.2014.04.004

Cite this

@article{be02284893d64bd3ac87c9a530813154,

title = "Inhaled versus nebulised tobramycin: A real world comparison in adult cystic fibrosis (CF)",

abstract = "Background: There are no published data on real-life clinical experience comparing inhaled antibiotic therapy via new rapid delivery systems with nebulised antibiotic therapy in CF. This real world study compares safety, effectiveness and tolerability using tobramycin inhaled powder (TIP) versus tobramycin inhaled solution (TIS). Methods: Adult patients with CF commencing TIP (n=78) completed a questionnaire assessing safety, efficacy, tolerability, patient-satisfaction and self-reported adherence to TIS at baseline and during 12months of TIP therapy. FEV1\% predicted and exacerbation rate were recorded at each visit. Results: There was a significant improvement in adherence scores, with a significant decrease in the number of intravenous antibiotic courses received during 12. months of TIP compared with the preceding 12. months using TIS. 94\% of patients who had previously used TIS preferred TIP therapy over TIS. Conclusions: Inhaled powder tobramycin in CF is associated with improved adherence, tolerability and decreased exacerbation rates compared to nebulised treatment in real-life practice.",

author = "Harrison, \{M. J.\} and M. McCarthy and C. Fleming and C. Hickey and C. Shortt and Eustace, \{J. A.\} and Murphy, \{D. M.\} and Plant, \{B. J.\}",

note = "Publisher Copyright: {\textcopyright} 2014 European Cystic Fibrosis Society.",

year = "2014",

month = dec,

day = "1",

doi = "10.1016/j.jcf.2014.04.004",

language = "English",

volume = "13",

pages = "692--698",

journal = "Journal of Cystic Fibrosis",

issn = "1569-1993",

publisher = "Elsevier B.V.",

number = "6",

}

TY - JOUR

T1 - Inhaled versus nebulised tobramycin

T2 - A real world comparison in adult cystic fibrosis (CF)

AU - Harrison, M. J.

AU - McCarthy, M.

AU - Fleming, C.

AU - Hickey, C.

AU - Shortt, C.

AU - Eustace, J. A.

AU - Murphy, D. M.

AU - Plant, B. J.

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Background: There are no published data on real-life clinical experience comparing inhaled antibiotic therapy via new rapid delivery systems with nebulised antibiotic therapy in CF. This real world study compares safety, effectiveness and tolerability using tobramycin inhaled powder (TIP) versus tobramycin inhaled solution (TIS). Methods: Adult patients with CF commencing TIP (n=78) completed a questionnaire assessing safety, efficacy, tolerability, patient-satisfaction and self-reported adherence to TIS at baseline and during 12months of TIP therapy. FEV1% predicted and exacerbation rate were recorded at each visit. Results: There was a significant improvement in adherence scores, with a significant decrease in the number of intravenous antibiotic courses received during 12. months of TIP compared with the preceding 12. months using TIS. 94% of patients who had previously used TIS preferred TIP therapy over TIS. Conclusions: Inhaled powder tobramycin in CF is associated with improved adherence, tolerability and decreased exacerbation rates compared to nebulised treatment in real-life practice.

AB - Background: There are no published data on real-life clinical experience comparing inhaled antibiotic therapy via new rapid delivery systems with nebulised antibiotic therapy in CF. This real world study compares safety, effectiveness and tolerability using tobramycin inhaled powder (TIP) versus tobramycin inhaled solution (TIS). Methods: Adult patients with CF commencing TIP (n=78) completed a questionnaire assessing safety, efficacy, tolerability, patient-satisfaction and self-reported adherence to TIS at baseline and during 12months of TIP therapy. FEV1% predicted and exacerbation rate were recorded at each visit. Results: There was a significant improvement in adherence scores, with a significant decrease in the number of intravenous antibiotic courses received during 12. months of TIP compared with the preceding 12. months using TIS. 94% of patients who had previously used TIS preferred TIP therapy over TIS. Conclusions: Inhaled powder tobramycin in CF is associated with improved adherence, tolerability and decreased exacerbation rates compared to nebulised treatment in real-life practice.

UR - https://www.scopus.com/pages/publications/84911956623

U2 - 10.1016/j.jcf.2014.04.004

DO - 10.1016/j.jcf.2014.04.004

M3 - Article

C2 - 24815094

AN - SCOPUS:84911956623

SN - 1569-1993

VL - 13

SP - 692

EP - 698

JO - Journal of Cystic Fibrosis

JF - Journal of Cystic Fibrosis

IS - 6

ER -

Inhaled versus nebulised tobramycin: A real world comparison in adult cystic fibrosis (CF)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this